Risk factors

Going concern doubt hangs over operations due to ongoing operating losses and a limited operating history. Reliance on the University of Pittsburgh license is absolute for the core SkinJect asset. Integration of recently acquired Antev and its Teverelix asset presents execution risk.

The supplied section is dominated by executive compensation, equity-plan mechanics, severance obligations and governance provisions.

MaxCyte faces Nasdaq delisting risks due to low share prices, supply chain disruptions, and tariff uncertainties in international trade.

Nkarta highlights new asset impairment charges from low stock prices, manufacturing scaling hurdles, and potential tariff impacts on single-source supplies.

The company faces continued losses, growing accumulated deficits, and risks regarding compliance with Nasdaq listing standards and internal control weaknesses. Financial disclosures updated figures for the years ended December 31, 2025 and 2024.

Oak Valley Bancorp shows minimal changes in its risk disclosures, indicating stability in its core banking operations and macro environment.

Everpure faces new financial risks from expanding flash storage sales to hyperscalers and navigating post-OBBBA international tax rules. The company refinanced its credit facility to an unsecured $500.0 million facility and raised product prices to offset higher component costs.

Park Dental Partners relies on contractual support arrangements with affiliated dental practices mainly located in Minnesota. Approximately 92 percent of revenue comes from insurance or government plans, with one payor providing over 30 percent. Operations depend heavily on recruiting clinicians and maintaining secure IT systems.

UiPath reports growing revenues and ARR for fiscal years 2025 and 2026, alongside completed ERP implementation and increased focus on privacy and share dilution risks.

Paysign combined two separate key personnel risks into one comprehensive risk factor. Stock price volatility range updated to reflect 2025 figures between $1.94 and $8.56.

Precigen transitioned to a commercial-stage company following FDA approval of Papzimeos for RRP, securing $125.0 million in debt financing and scaling up launch and manufacturing risks.

ProMIS Neurosciences faces risks from third-party reliance for manufacturing and clinical trials of product candidates like PMN310. Nasdaq compliance issues and intellectual property enforcement dominate the risk profile. Integration of artificial intelligence introduces new operational and cybersecurity vulnerabilities.